NCT04941313View on ClinicalTrials.gov

Phase 1 Study of 3D229 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

November 15, 2021

Study Completion Date

February 21, 2022

Conditions

Healthy Subject

Interventions

DRUG

3D229

3D229 is an investigational drug.

OTHER

Placebo

Matching placebo

Trial Locations (1)

201321

Shanghai General hospital, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

lead

3D Medicines

INDUSTRY